Physician profile
Coretta H Collins
NPI 1104258532
$77,012.66
in general payments reported to CMS, 2019-2025
47 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,036 · 2022: $15K · 2023: $13K · 2024: $28K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Travel and Lodging: $16K · Consulting Fee: $4,260 · Food and Beverage: $2,758 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,000.00 |
| Travel and Lodging | $16,158.81 |
| Consulting Fee | $4,260.00 |
| Food and Beverage | $2,758.23 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $64,223.50 | 2021-2025 | Retevmo, Verzenio, Jaypirca |
| Global Blood Therapeutics, INC. | $4,759.45 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $1,742.95 | 2021-2025 | |
| Pfizer INC. | $1,667.90 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $607.98 | 2021-2022 | |
| Abbvie INC. | $441.38 | 2021-2023 | |
| Amgen INC. | $361.70 | 2021-2022 | |
| Seagen INC. | $298.51 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $290.69 | 2021-2025 | Imfinzi |
| Merck Sharp & Dohme LLC | $217.75 | 2021-2022 | |
| Genzyme Corporation | $168.17 | 2021-2022 | |
| Janssen Biotech, INC. | $152.24 | 2021-2022 | |
| Incyte Corporation | $152.04 | 2021 | |
| Beigene USA, INC. | $145.02 | 2021-2022 | |
| Celgene Corporation | $141.12 | 2021-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Coretta Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.